Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997: Vol 16 Index

7 Pages·1997·1.5 MB·English

AUTHOR INDEX
Hirozawa AM, [82 Lal RB, 308 Nakamura M, 380
Hoff R, 195 Landay AL, 161 Nath A, 223
Hofmann B, 10 Lange JMA, 318 Nauclér A, 31
Holbrook KA, 301 Larsen O, 31 Nelson KE, 293
Holden-Wiltse J, 247 Larsen R, 100 Ngom PT, 327
Holtgrave DR, 54 Lau J, 22 Nguyen HT, |
Hoover DR, 293 Ledergerber B, 153 Nielsen C, 93
Hoxie NJ, 367 Lee CA, 279 Nielsen JO, 153
Hoy JF, 39 Leitner T, 31 Norrgren H, 31
Hsu LC, 182 Lemp GF, 182 Nunez CA, 308
Hughes JP, 243 Lavy, 39
Hughes MD, 22 Limjoco MT, 100 Oliver G, 190
Hultin LE, 83 Lingo M, 182 Ono F, 313
Hurwitz JL, 69 Liu Z, 83 Otani I, 313
Hyer CJ, 362 Livermore T, 190
Lobo M, 307 Padian N, 127
Ioannidis JPA, 22 Lorvick J, 211 Padnick J, 161
Iversen AKN, 10 Loubeau M, 137 Page JB, 272
Lowry FD, 301 Pakker NG, 318
Jacobson JM, 100 Lundgren JD, 93, 153 Parekh B, 308
Jacquez JA, 284 Patrel D, 204
Jaffar $, 327 Machida M, 313 Pauli G, 333
Janossy G, 279 Maclean I, 293 Pedersen C, 10, 93, 153
Jassoy C, 74 MacQueen KM, 108 Peeters M, 204
John TJ, 357 Mallal SA, 39 Petit J-C, 176
Johnson AM, 153 Marmor M, 393 Petito CK, 146
Jones JL, 374 Marquina S, 31 Petrucci A, 411
Jose-Burbano M, 272 Massad S, 161 Pezzotti P, 411
Judson FN, 108 Mastro TD, 393 Phillips AN, 153, 279
Junge B, 400 Mavoungou E, | Pinkerton SD, 54
Just JJ, 239 Mayer KH, 408 Poaty-Mavoungou V, |
McAnulty JM, 362 Porco TC, 182
Kahn JO, 266 McKirnan D, 108 Poulsen A-G, 31
Kaldor JM, 39 McLellan CL, 243 Powderly W, 100
Karon JM, 116 Meehan PM, 247 Pramilabai A, 357
Kassman BP, 243 Melbye M, 31 Prince HE, 83
Katlama C, 153 Melvin AJ, 243
Katz MH, 182 Menezes J, 137 Quesada JA, 272
Katzenstein T, 93 Meng TC, 247
Katzenstein TL, 10 Meynard J-L, 176 Rabian C, 340
Kawano Y, 380 Meyohas M-C, 176 Raktham S, 393
Keefer MC, 100 Meza R, 308 Reicken E-O, 333
Khayam-Bashi H, 169 Miedema F, 318 Reiser WJ, 367
King M-C, 239 Mijch AM, 39 Reiss P, 153, 318
King PD, 243 Mizusawa H, 380 Rencher SD, 69
Kira J-i, 380 Modahl LE, 169 Rezza G, 411
Kitayaporn D, 393 Modesitt SK, 362 Rich JD, 408
Klein RS, 301 Mohan KM, 243 Richman DD, 247
Kobayashi T, 380 Mohle-Boetani JC, 190 Rida W, 195
Kojima E, 313 Moore L, 44 Riley E, 400
Koot M, 318 Moore RD, 15 Rimaniol A-C, 340
Koppelhus U, 10 Mori K, 313 Rolfe M, 327
Korzun AH, 100 Mueller GE, 122 Ronald A, 293
Koulinska I, 407 Mukai R, 313 Roos MTL, 318
Koyanagi Y, 380 Mulanga-Kabeya C, 204 Rothschild LH, 301
Kral AH, 211 Miiller M, 74 Rousseau CM, 239
Kuntolbutra S, 293 Murakami K, 313 Royce S, 190
Kusunoki S, 380 Murante BL, 243 Ruef C, 230
Kutsch O, 74 Murphy EL, 169 Russo-Marie F, |
Murphy JT, 122 Rydman RJ, 161
Lai H, 272 Murri R, 350
Lai KK, 100 Mwchari C, 63 Saag M, 247
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997
416 AUTHOR INDEX
Sabally S, 327 Suprasert S, 293 Whalen JJ III, 254
Sabin CA, 279 Svejgaard A, 10 Wheat J, 100
Sacks HS, 22 Whitman S, 122
Salhi Y, 409 Takasaka M, 313 Whittle HC, 327
Salmon M, 44 Takena H, 204 Wilkins A, 327
San Miguel LG, 307 Tanaka Y, 380 Wilkinson D, 50
Sauberlich H, 272 Tasker SA, 219 Wilson IB, 343
Schellekens PTA, 318 Terrell S, 308 Woelffer G, 182
Schmidt W, 333 Tilleul P, 176 Wolfe H, 393
Schneider D, 100 Titus S, 393
Schneider T, 333 Toma E, 137 Yaba P, |
Scoppettuolo G, 350 Trino R, 44 Yamamoto I, 380
Segurado A, 308 Tsuneyoshi M, 380 Yamamoto N, 380
Sha BE, 161 Yamasaki K, 380
Ullrich R, 333
Shapshak P, 146 Yetunde O, 204
Shinohara YT, 219 van Leeuwen R, 318 Yoshida T, 380
Shor-Posner G, 272 Vanichseni S, 393 Yoshikawa Y, 313
Simpson M, 100 Varney KF, 169 Yoshino S, 380
Skahan KJ, 100 Vaz P, 407 Young KC, 169
Snyder DC, 190 Vella S, 153 Yusem SH, 362
Sopper S, 74 Vergeront JM, 367
Sgrensen AM, 10 Viard J-P, 340 Zavala F, 340
Spear GT, 161 Viahov D, 400 Zeitz M, 333
Squires K, 100 Volberding PA, 22 Zenilman JM, 293
Squires KE, 247 Zhang G, 272
Sripriya G, 357 Wahnschaffe U, 333 Zippel T, 333
Stakteas S, 407 Ward JW, 116, 374 Zule WA, 309
Stein Z, 239 Warner NA, 161 Zwandor A, 204
Strasser F, 230 Watters JK, 211 Zylberberg H, 340
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
16:417—421 © 1997 Lippincott-Raven Publishers, Philadelphia
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 16, 1997
Subject Index
Abscess, risk in HTLV-II-seropositive injection drug users, Bacterial infection
169 macrophage-related proteins and, 230
Acquired immunodeficiency syndrome tisk in HTLV-II-seropositive injection drug users, 169
CD38 antigen expression as marker for risk of, 83 Baltimore, needle exchange program in, 393
high cytomegalovirus antigenemia levels and (letter), 307 Bisexual men, HIV trends in, 374
illness trends in Australia from 1983 to 1994, 39 Boric acid, to control azole-refractory Candida vaginitis (let-
neurologic complications of, 340 ter) 249
tuberculosis co-occurrence with, 44
Acute-phase proteins, elevated serum levels in advanced
HIV, 230
Cachexia, testosterone replacement for in HIV-infected men.
Adolescents, HIV trends in gay and bisexual, 374
254
Africa Calprotectin, in advanced HIV infection, 230
HIV infection pathogenesis in, 327 Candida vaginitis, azole-refractory, boric acid in controlling
HIV seroprevalence in, 204 (letter), 219
HIV-1 subtypes in (letter), 63 CCRS receptors, in mother-to-infant transmission risk, 243
Agarose gels, in HIV-1 subtyping (letter), 218 CCRSdel32, in perinatal HIV-1! infection, 239
AIDS. See Acquired immunodeficiency syndrome; HIV-2 CCRSdel32/CCRS5 genotype, HIV RNA levels and CD4 cell
infection; HIV-1 infection; Human immunodeficiency counts with, 10
virus CD38 antigen expression, on CD8* cells, 83
AIDS/HIV epidemic CD4 cell count
heterosexual, redefining growth of in Chicago, 122 in asymptomatic carriers and AIDS cases, 31
peak and decline of in San Francisco, 182 with CCR5832/CCRS5 genotype vs. wild type, 10
trends in adolescent and young adult gay and bisexual prognostic value of, 93
men, 374 rate of decline in HIV-1 vs. HIV-2 infection, 327
Anabolic steroids, for HIV-infected men, 254 reporting of in AIDS surveillance, 362
Androgen replacement options, for HIV-infected men, 254 in sex workers in India, 357
Anemia, risk in HTLV-II-seropositive injection drug users, CD4*cell count
169 in advanced HIV infection, 230
Antibody-dependent cellular cytotoxicity (ADCC) effector in cryptosporidiosis, 367
activity, enhancement of, 137 in HIV disease progression, 83
Antibody-dependent cytolytic activity, enhancement of, 137 simplified procedures for (letter), 408
Antioxidants, inhibiting HIV-1 gp120-induced free radical- CD4 ‘cells
based oxidative damage, 223 depletion of and memory cell loss, 74
Antiretroviral therapy rate of decline in HIV-1 vs. HIV-2 infection, 327
patient loss to follow-up in long-term randomized trial of, CD8 ceils
22 CD38 antigen expression on, 83
regional differences in Europe, 153 count in sex workers in India, 357
T-cell repopulation, virus load reduction, and T-cell func- soluble, 83
tion restoration during, 318 CD4 cells, antiretroviral agents and, 318
Antiviral therapy CD30 levels, disease progression and in hemophiliac men,
regional differences in use of, 153 279
T-cell repopulation, virus load reduction, and T-cell func- Cerebrospinal fluid, interleukin-1 and interleukin-1 receptor
tion restoration during, 318 antagonist balance in, 340
Arthritis, chronic, in HTLV-I, 380 Cervicovaginal fluid, immunologic markers in, 161
Asymptomatic carriers, HIV-2 genetic variation and DNA Chemokines, macrophage-related proteins and, 230
load in, 31 Chicago, heterosexual HIV/AIDS epidemic in, 122
At-risk populations, in San Francisco, 182 6-Chloro-2,’3'-dideoxyguanosine, efficacy on monkeys
Australia, trends in AIDS incidence in from 1983 to 1994, 39 chronically infected with SIV, 313
418 SUBJECT INDEX
Chronic inflammatory arthropathy, induction in HTLV-I in- Epidemic. See AIDS/HIV epidemic
fection, 380 Epidemiology
Clinical progression, with CCR5832/CCRS5 genotype vs. wild of Clostridium difficile-associated diarrhea in HIV infec-
type, 10 tion, 176
Clinical trials of drug-using lesbians, 211
of combination therapy with zidovudine, zalcitabine, and Europe, 153
interferon, 247 Ethnic groups, HIV epidemic trends in gay and bisexual men
for HIV vaccine candidate evaluation, 195 in, 374
of itraconazole maintenance treatment, 100 Europe, regional difference in antiretroviral use in, 153
patient loss to follow-up in, 22 Exposure categories, misclassification of, 122
Clostridium difficile diarrhea, in HIV-infected patients, 176
Collagen, Type II, in chronic inflammatory arthropathy and
mesenchymal tumor induction, 380 Female genital tract, immunologic response to HIV in, 161
Combination therapy, safety and antiviral activity of, 247 Flow cytometry
Cost analysis, of HIV/AIDS, 54 of CD38 antigen expression on CD8°T cells, 83
Cost-benefit analysis of HIV-1 glycoprotein expressing cells, 74
for HIV prevention programs, 54 Follow-up study, patients lost to, 22
of prophylactic ganciclovir treatment, 15 Functional status, clinical predictors of decline in, 343
Crack cocaine, HIV risk profile of lesbians using, 21]
Cryptosporidiosis, massive waterborne outbreak of in HIV-
infected persons, 367 Gambia, HIV infection pathogenesis in, 327
Cytokines Ganciclovir, prophylactic, for cytomegalovirus retinitis, 15
in cervicovaginal fluid, 161 Gay men
macrophage-related proteins and, 230 HIV trends in, 374
Cytomegalovirus antigenemia, in AIDS patients (letter), 307 willingness to participate in vaccine trials, 108
Cytomegalovirus retinitis, prophylactic oral ganciclovir for, Genetic variation, HIV-2, 31
15 gp120-induced free radical-based oxidative damage, inhibi-
Cytomegalovirus syndrome, high cytomegalovirus antigen- tion of, 223
emia levels and (letter), 307 Guinea-Bissau, HIV-2 genetic variation and DNA load in
asymptomatic carriers and AIDS cases in, 31
Decision analysis, cytomegalovirus retinitis prophylaxis, 15
Dementia, HIV-1-associated, 146 Haemophilus ducreyi infection, association with HIV infec-
Diagnosis, pediatric AIDS (letter), 407 tion in northern Thailand, 293
Diarrhea Health status, quality of life and in HIV-infected patients,
Clostridium difficile-associated, 176 350
in cryptosporidiosis, 367 Health-related quality of life
Dipyridamole, inhibiting HIV-1 gp120-induced free radical- clinical predictors of decline in, 343
based oxidative damage, 223 with nonadvanced HIV infection, 350
Disease outbreak, in HIV-infected persons, 367 Hemophilia, CD30 levels levels after HIV seroconversion in,
Disease progression 279
CCRS5del32 in, 239 Hepatitis C, HIV and in male prisoners (letter), 408
CD38 antigen expression and, 83 Herpes simplex virus type 2, association with HIV infection
CD30 levels levels after HIV seroconversion and, 279 in northern Thailand, 293
serum HIV-RNA levels and, 93 Heteroduplex mobility assay, in HIV-1 subtyping (letter),
Disease stage, mother-to-child transmission and, 284 218
Disease-related factors, in health-related quality of life, 350 Heterosexual transmission, misclassified in Chicago, 122
DNA load, in asymptomatic carriers and AIDS cases, 31 Histoplasmosis, itraconazole maintenance treatment for, 100
Drug injection equipment, HIV risk and (letter), 309 HIV. See Acquired immunodeficiency syndrome; HIV-2 in-
Drug users. See Injection drug users; Substance abuse fection; HIV-1 infection; Human immunodeficiency
Duodenal biopsy, IgG in HIV-specific antibodies of, 333 virus
HIV envelope glycoproteins
SIV envelope glycoproteins and, |
Economic evaluation, of HIV/AIDS, 54 V1-VZ sequence diversity effect, 69
ELISA test HIV epidemic. See AIDS/HIV epidemic
of HIV-1 envelope V1-V2 sequence diversity, 69 HIV-1 group O, seroprevalence of in Nigeria, 204
in pediatric AIDS diagnosis (letter), 407 HIV-1 infection
Encephalitis, HIV-1-associated, 146 dementia of, proviral DNA load and, 146
Envelope glycoproteins enhancing natural killer and ADCC activities against, 137
memory cell loss and CD*T lymphocyte depletion with, mother-to-child transmission of, 284
74 nutritional deficiencies and, 272
in phospholipase A, activation, | rate of CD4 cell decline in, 327
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997
SUBJECT INDEX
HIV-2 infection Injection drug users
genetic variation and DNA load in asymptomatic carriers infectious disease risk in HTLV-II seropositive, 169
and AIDS carriers, 31 lesbian, HIV risk profile of, 211
rate of CD4 cell decline in, 327 nutritional deficiencies and, 272
HIV RNA reduction of risk behaviors in, 393
with CCR5832/CCRS genotype vs. wild type, 10 Staphylococcus aureus nasal colonization in, 301
simplified procedures for quantifying (letter), 408 vaccine trials and HIV risk reduction in, 393
HIV seroconversion rates, in projected AIDS incidence, 182 Interferon, safety and antiviral activity of combination
HIV seroprevalence, in Nigeria, 204 therapy with, 247
HIV-1 subtypes Interleukin-15, in enhancement of natural killer and anti-
heteroduplexes on Agarose gels (letter), 218 body-dependent cytolytic activities, 137
in Nairobi, Kenya (letter), 63 Interleukin-1, interleukin-1 receptor antagonist and in cere-
HIV vaccine brospinal fluid, 340
evaluation of candidates for, 195 Interleukin-2 receptor, soluble, 83
in long-term HIV risk reduction, 393 Interleukin-1 receptor antagonist, interleukin-1 and in cere-
risk behaviors in trial participants for, 266 brospinal fluid, 340
HIV-specific antibodies, IgG predominance in, 333 Intestinal mucosa, IgG predominance in HIV-specific anti-
HLA-DR expression, in HIV disease progression, 83 bodies in, 333
Homosexuality, HIV epidemic trends and, 374 Iron, gp120-induced reactive oxygen species and, 223
Honduras, HTLV-I and HTLV-II infection in (letter), 308 Italy, health-related quality of life in HIV-infected patients
HTLV-I in, 350
chronic inflammatory arthropathy and mesenchymal tu- Itraconazole maintenance, for histoplasmosis, 100
mors in, 380
in Honduras (letter), 308
HTLV-II
Kenya, HIV-1 subtypes in (letter), 63
in Honduras (letter), 308
infectious disease risk with in injection drug users, 169
Human immunodeficiency virus
Clostridium difficile-associated diarrhea in, 176 Latin America, HTLV-I and HTLV-II infection in (letter),
HSV-2, Haemophilus ducreyi, and syphilis associated 308
with, 293 Lesbians, drug-using, HIV risk profile of, 211
interleukin-! and interleukin-1 receptor antagonist balance Letters to editor
in, 340 diagnosing pediatric AIDS in resource-poor settings, 407
long-term nonprogression in (letter), 409, 411 hepatitis C and HIV in male prisoners, 408
in male prisoners (letter), 408 high cytomegalovirus antigenemia levels and cytomegalo-
quality of life with, 350 virus syndrome in patients with AIDS, 307
tuberculosis attributable to, 190 HIV-1 subtypes in Nairobi, Kenya, 63
Hypogonadism, testosterone replacement for in HIV-infected long-term nonprogression in HIV infection, 409
men, 254 long-term nonprogression in HIV infection: authors’ reply,
411
presence of HTLV-I and HTLV-II infection in Honduras,
IgA
anti-HIV, in pediatric AIDS diagnosis (letter), 407 308
simplified procedures for enumeration of CD4*T lympho-
secretory, 333
cytes and quantification of HIV RNA, 408
IgG, in intestinal HIV-specific antibodies, 333
subtyping HIV-1 by improved resolution of heteroduplexes
Immune activation, in HIV disease progression, 83
on Agarose gels, 218
Immune response, in female genital tract, 161
successful use of boric acid to control azole-refractory
Immunoglobulins, in sex workers in India, 357
Candida vaginitis in a woman with AIDS, 219
Immunologic markers, in cervicovaginal fluid of HIV-in-
various types of injection equipment and risk of HIV in-
fected vs. uninfected women, 161
fection, 309
Immunologic profiles, in Indian commercial sex workers,
Leukocytes, in sex workers in India, 357
357
Long-term randomized trial, patient loss to follow-up in, 22
Immunology, in sex workers in India, 357
Lymphadenopathy, risk in HTLV-II-seropositive injection
Incidence, AIDS/HIV
drug users, 169
of AIDS-defining opportunistic illness diagnoses, 116
Lymphocyte activation markers, in men with hemophilia, 279
in gay and bisexual men, 374
Lymphocytes
projection of in San Francisco, 182
count of in sex workers in India, 357
Incubation period, in projected AIDS incidence, 182
phospholipase A, activation in, |
India, immunologic profiles of HIV-infected and uninfected
sex workers in, 357
Infants, CCRS receptors and HIV-1 transmission to, 243
Infectious disease, risk in HTLV-II-seropositive injection Macrophage inhibitory factor-related protein 8/14, elevated
drug users, 169 serum levels in advanced HIV, 230
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997
420 SUBJECT INDEX
Macrophage-related proteins, elevated serum levels in ad- in rural South Africa, 50
vanced HIV, 230 Prevention programs
Memory cells, loss of and CD*T lymphocyte depletion, 74 economic evaluations of, 54
Mesenchymal tumor, induction in HTLV-I infection, 380 needle exchange programs in, 393
82-Microglobulin universalistic and targeted strategies of, 127
in HIV disease progression, 83 Prisoners, hepatitis C and HIV infection in (letter), 408
macrophage-related proteins and, 230 Prognosis
Milwaukee, waterborne cryptosporidiosis outbreak in, 367 with CD30 levels in hemophiliac men, 279
Monoclonal antibody, HIV-1 envelope V1-V2 sequence di- predictors of in AIDS patients, 343
versity effect on, 69 Prognostic markers
of HIV disease progression, 83
serum HIV-RNA levels as, 93
Prophylaxis, regional differences in use of, 153
Mother-to-infant transmission Proviral DNA load, in HIV-1-associated dementia, 146
CCRS receptors and, 243 Public health registries, of AIDS and tuberculosis co-occur-
HIV-1 infection, 284 rence, 44
Mucosal immunity, in female genital tract, 161
Quality of life
Nairobi, HIV-1 subtypes in (letter), 63 clinical predictors of decline in, 343
Nasal colonization, in HIV-seropositive drug users, 301 in economic evaluation of HIV prevention, 54
Natural history, serum HIV-RNA levels and, 93 in HIV-infected patients, 350
Natural killer activity, enhancement of, 137 Quantitative fluorescence, of CD38 antigen expression on
Needle exchange program, reduction of high-risk drug use CD8'T cells, 83
behaviors in, 393
Neopterin, in HIV disease progression, 83
Neuroanatomic regions, HIV-1 proviral DNA load across,
146 Randomized controlled trials, for HIV vaccine candidate
Neurologic complications, AIDS-related, 340 evaluation, 195
New York, vaccine trials and HIV risk reduction in, 393 Reactive oxygen species, gp120-induced, 223
Nigeria, HIV seroprevalence in, 204 Regional variation, in use of antiretroviral agents, 153
*‘No identifiable risk’’ category, redefinition of, 122 Rhesus macaques, 6-chloro-2,’3'-dideoxyguanosine efficacy
Nutritional deficiencies, with HIV-1 infection in women, 272 with chronic SIV infection, 313
Risk, HIV
drug injection equipment and (letter), 309
Opportunistic infections in drug-using lesbians, 211
in AIDS illnesses in Australia, 39 long-term reduction of, 393
AIDS-defining, estimating number of, 116 Risk behavior
risk in HTLV-II-seropositive injection drug users, 169 in injection drug users, 393
in preventive HIV vaccine trial participants, 266
vaccine trials and HIV risk reduction with, 393
Rural areas
p24 antigen, in pediatric AIDS diagnosis (letter), 407
HIV seroprevalence in, 204
Pathogenesis, of HIV-1 vs. HIV-2, 327
increasing HIV prevalence in, 50
Patient loss, to follow-up in long-term randomized trails, 22
Pediatric AIDS, in resource-poor settings (letter), 407
Perinatal transmission
CCRS receptors and, 243 San Francisco, projected AIDS incidence in, 182
HIV-1 infection, CCR5del32 in, 239 Seroconversion, serum HIV-RNA levels after, 93
Peripheral blood mononuclear cells, natural killer and anti- Serotyping, for Clostridium difficile-associated diarrhea in
body-dependent cytolytic activities of, 137 HIV infection, 176
Phase III HIV vaccine trials, willingness to participate in, Serum HIV-RNA levels, prognostic value of, 93
108 Sex hormones, for HIV-infected men, 254
Phospholipase A,, activation of, HIV and SIV envelope gly- Sex workers, immunologic profiles of HIV-infected and un-
coproteins in, | infected, 357
Physical function, clinical predictors of decline in, 343 Sexual risk behavior, in HIV vaccine trial participants, 266
Pneumonia, risk in HTLV-II-seropositive injection drug us- Sexual transmission, in drug-using lesbians, 211
ers, 169 Sexually transmitted disease, in young men in Thailand, 293
Polymerase chain reaction, quantitative, in determining Simian immunodeficiency virus, efficacy of 6-chloro-2,'3'-
HIV-1 proviral DNA load across neuroanatomic re- dideoxyguanosine on monkeys with, 313
gions, 146 SIV envelope glycoproteins, HIV envelope glycoproteins
Prevalence, AIDS/HIV and, |
HIV vaccine trials and, 393 South Africa, rural, increasing HIV prevalence in, 50
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997
SUBJECT INDEX 42]
Staphylococcus aureus nasal colonization, in HIV-seroposi- United States, HIV epidemic trends in gay and bisexual men
tive and -seronegative drug users, 301 in, 374
Statistical analysis, of AIDS-defining opportunistic illness Universalistic HIV prevention, strategies for, 127
diagnoses, 116
Substance abuse. See also Injection drug users
HIV risk reduction and, 393
Vaccine trials
reduction of risk behaviors with, 393
in long-term HIV risk reduction, 393
Surveillance
risk behaviors in participants in, 266
of AIDS and tuberculosis co-occurrence, 44
willingness to participate in, 108
AIDS definition, 116
Vaccines, evaluation of candidates for, 195
improved, through laboratory-initiated CD4 cell count re-
Variable regions, of HIV-1 envelope, 69
porting, 362
Vellore region, immunologic profiles of HIV-infected and
Syphilis, association with HIV infection in northern Thai-
uninfected sex workers in, 357
land, 293
Vertical transmission
CCRS receptors and, 243
HIV-1 infection, 284
Targeted HIV prevention, strategies for, 127
Viral load
Tax protein, in chronic inflammatory arthropathy and mesen-
after seroconversion, 93
chymal tumor induction, 380
with CCR5832/CCRS genotype vs. wild type, 10
T-cell function, in HIV-infected persons during antiviral
in HIV-infected persons during antiviral therapy, 318
therapy, 318
Virologic steady state, serum HIV-RNA levels at, 93
T-cell repopulation patterns, during antiviral therapy, 318
Testosterone replacement, for HIV-infected men, 254
Thailand
HSV-2, Haemophilus ducreyi, and syphilis associated with Wasting, testosterone replacement for in HIV-infected men,
HIV infection in, 293 254
vaccine trials and HIV risk reduction in, 393 Water supply, Cryptosporidium in, 367
Thiobarbituric acid-reactive substances assay, to measure Weight loss, testosterone replacement for in HIV-infected
gp120-induced oxidative damage, 223 men, 254
Time trends, in AIDS illnesses in Australia, 39 Wild type genotype, HIV RNA levels and CD4 cell counts
Transmission mode with, 10
heterosexual, misclassified, 122 Women
mother-to-infant, 243, 284 azole-refractory Candida vaginitis in (letter), 219
Treatment effect, patient loss to follow-up in long-term trials HIV-1 infection with severe nutritional deficiencies in, 272
of, 22 immunologic markers in cervicovaginal fluid of, 161
Tuberculosis
co-occurrence with AIDS, 44
incidence attributable to HIV infection, 190 Zalcitabine, safety and antiviral activity of combination
Tumor necrosis factor-a-receptor type II, soluble, 83 therapy with, 247
Zidovudine
patient loss to follow-up in long-term trials of, 22
U937 cells, gp120-induced reactive oxygen species damag- safety and antiviral activity of combination therapy with,
ing, 223 247
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 16, No. 5, 1997